SCHEMBL6093680

SCHEMBL6093680

O=C1c2c(-c3ccc(F)cc3)cc(N3CCC(N4CCCC4=O)CC3)nc2OCCCN1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.38
HRH1 P35367 1/20 0.38
CTSS P25774 1/20 0.37
GRM2 Q14416 3/20 0.35
TACR1 P25103 5/20 0.35
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34
TNIK Q9UKE5 3/20 0.34
SCD O00767 1/20 0.33
AURKA O14965 1/20 0.33
FLT1 P17948 1/20 0.33
GCK P35557 1/20 0.33
FLT4 P35916 1/20 0.33
MAP3K11 Q16584 1/20 0.33
STK17A Q9UEE5 1/20 0.33
ENPP2 Q13822 1/20 0.33
CASP1 P29466 1/20 0.32
CASP5 P51878 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092544 0.90 TACR1 (0.38) TACR1ROCK2ROCK1TNIKAURKA
SCHEMBL6093388 0.88 TACR1 (0.35) CYP2D6TACR1ROCK2ROCK1TNIK
SCHEMBL6094847 0.87 TACR1 (0.36) CYP2D6HRH1CTSSTACR1ENPP2
SCHEMBL6096328 0.87 TACR1 (0.38) CYP2D6HRH1GRM2TACR1ROCK2
SCHEMBL6092166 0.85 CNR1 (0.39) CYP2D6GRM2TACR1ROCK2ROCK1
SCHEMBL6095651 0.83 CTSS (0.38) CYP2D6HRH1CTSSTACR1ROCK2
SCHEMBL6094098 0.83 SMO (0.40) TACR1ROCK2ROCK1TNIKAURKA
SCHEMBL6094210 0.83 TACR1 (0.37) TACR1ROCK2ROCK1TNIKCASP1
SCHEMBL6093672 0.83 TACR1 (0.40) TACR1ROCK2ROCK1CASP1CASP5
SCHEMBL6092004 0.82 TACR1 (0.39) TACR1ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030107-B2 nitrogen compounds such as 5-[3,5-bis(trifluoromethyl)benzyl]-6-oxo-7-phenyl-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine, used as neurokinin inhibitors for prophylaxis of urogenital disorders; side effect reduction KYORIN PHARMACEUTICAL.CO., LTD. (JP) 2006-04-18 US disclosed
US-20050107375-A1 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-05-19 US disclosed
EP-1457493-A1 FUSED BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS Kyorin Pharmaceutical Co., Ltd. (JP) 2004-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107375-A1 Fused bicyclic pyridine derivatives as tachykinin receptor antagonists BDKRB1, BDKRB2, TACR1 CYP2D6 2618/4885HRH1 32/4885CTSS 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.